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Background: Different antiretroviral therapies (ARTs) may have differing effects on central nervous system
(CNS) function. We assessed CNS pharmacodynamic effects of switching integrase inhibitors in people-
with-HIV (PWH).
Methods: PWH on tenofovir-DF/emtricitabine plus raltegravir 400mg twice daily with suppressed plasma
HIV RNA and without overt neuropsychiatric symptoms were randomly allocated on a 1:2 basis to remain
on raltegravir or switch to dolutegravir 50mg once daily for 120days. Pharmacodynamic parameters
assessed included cognitive function (z-score of 7 domains), patient-reported outcome measures (PROMs;
PHQ-9 and Beck’s depression questionnaires), cerebral metabolite ratios measured by proton magnetic res-
onance spectroscopy (H1-MRS) and plasma and cerebrospinal fluid (CSF) HIV RNA. Pharmacokinetic
parameters were also assessed in plasma and CSF. Changes and factors associated with changes in
pharmacodynamics parameters were assessed.
Results: In 20 subjects (19 male, 14 white ethnicity, median age 43 years (IQR: 11.5) and CD4þ count 717
(SD: 298) cells/mL), over 120days there were no statistically significant changes in cognitive function [mean
z-score difference (95%CI) 0.004 (0.38/0.37); p¼ 0.98], PROMs [PHQ-9 median score change: 0 in con-
trol arm, 0.5 switch arm (p¼0.57); Beck’s depression questionnaire: 1.5 control arm, 1.0 switch arm
(p¼ 0.38)], nor cerebral metabolite ratios between study arms. CSF HIV RNA was <5 copies/mL at baseline
and day 120 in all subjects. Geometric mean pre-dose CSF dolutegravir concentration was 7.6ng/mL (95%
CI: 5.2–11.1).
Conclusions: Switching integrase inhibitor in virologically suppressed PWH without overt neuropsychiatric
symptoms resulted in no significant changes in an extensive panel of CNS pharmacodynamics parameters.
KEYWORDS: Cognitive function, integrase inhibitor, raltegravir, dolutegravir, CNS, MR spectroscopy; CSF
Introduction
Modern effective antiretroviral therapy (ART) sup-
presses plasma viremia and allows restoration of
immune system function in persons with HIV (PWH).
Consequently, in ART treated PWH, AIDS defining
illnesses are now rare and life expectancy approaches
that of the general population.1 However, when com-
pared to the general population, the prevalence of non-
infectious co-morbidities are reported to be greater
and quality of life is described to be poorer in PWH.2
Central nervous system (CNS) disorders are one
group of conditions which remain highly prevalent in
otherwise effectively treated PWH. This includes
neuropsychiatric disorders such as depression, anxiety
and cognitive impairment.3,4 Evidence suggests that
different antiretroviral agents and combinations may
have differing effects on cerebral function and neuro-
psychiatric symptomatology.5–7 The non-nucleoside-
reverse-transcriptase-inhibitor efavirenz has well docu-
mented neuropsychiatric side effects8 and in more
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recent years, a host of CNS side effects (such as sleep
disorders, dizziness, depression or anxiety) have been
reportedly associated with the use of the HIV-integrase
strand-transfer-inhibitors.9–13 These CNS side effects
have been more frequently observed in certain popula-
tions, such as older patients, female individuals or in
PWH with underlying depression or anxiety
disorders.14,15
Our aim here was to assess the pharmacodynamic
effects on the CNS of two different integrase-inhibitor
containing ART regimens. To assess this, we
employed a comprehensive battery including cognitive
assessments, patient reported outcome measures
(PROMs), measurement of CNS metabolites using
in vivo magnetic resonance spectroscopy (MRS) imag-
ing and measurement of several cerebrospinal fluid
parameters including HIV-1 RNA, soluble biomarkers
and infectivity markers. Pharmacokinetic parameters
were also assessed and included integrase-inhibitor
drug exposure in plasma and cerebrospinal fluid.
Methods
Subject selection and study design
This prospective, randomized, single center, proof of
concept study was conducted at St. Mary’s Hospital
(Imperial College Healthcare NHS Trust, London, UK)
from July 2015 to August 2016. PWH on ART com-
prising of raltegravir 400mg twice daily plus tenofo-
vir/emtricitabine 245/200mg (TruvadaTM) with an
undetectable plasma HIV-1 RNA for at least 3months
with no neurological or cognitive complaints were eli-
gible. Exclusion criteria included previous exposure to
dolutegravir, significant neurological disease, current
history of major depression or psychosis, recent head
injury (prior 3 months) and current alcohol abuse or
drug dependence.
Individuals were randomized on a 1:2 basis to either
remain on raltegravir (control arm) or to switch inte-
grase inhibitor from raltegravir to dolutegravir 50mg
once daily (switch arm). At baseline and after
120 days, all subjects underwent assessment of cerebral
function parameters.
Ethical considerations
Local human ethics committee approval was granted
prior to recruiting participants by the National
Research Ethics Service Committee London-Central,
UK (REC number 14/LO/1864). All participants were
required to sign an informed consent before under-
going any screening procedures. The study was regis-
tered on the European Clinical Trials Database
(EudraCT number 2014-003710-84).
Cerebral function parameters
Cognitive testing and patient reported outcome measures
Cognitive testing and PROMs were undertaken at
baseline, day 60 and day 120. Cognitive testing com-
prised of a computerized battery (CogStateTM Ltd,
Melbourne, Australia) which has been validated for
cognitive testing in several disease areas including
HIV.16 The battery undertaken in this study took
approximately 30min to complete and comprised of 7
specific tests covering several cognitive domains
(attention, psychomotor function, visual and working
memory and associate learning). PROMs were
Lawton’s instrumental activities of daily living scale,17
Patient Health Questionnaire-9 (PHQ-9)18 and Beck’s
depression questionnaires.19
Neuroimaging
Cerebral proton magnetic resonance spectroscopy (1H-
MRS) was performed on a Siemens MAGNETOMTM
Verio 3 Tesla scanner (Siemens Healthcare GmbH,
Erlangen, Germany) at baseline and day 120 with
methods previously described in detail.20
Post-processing of MRS were analyzed using the
time-domain fitting algorithm Totally Automatic
Robust Quantitation in NMR (TARQUINTM) (version
4.3.5).21 Metabolites identified included N-acetyl
aspartate (NAA), Choline (Cho), myo-inositol (mI),
and creatine (Cr) with all metabolites expressed as
ratios to Cr.
Cerebrospinal fluid parameters
Cerebrospinal fluid examinations were undertaken at
baseline and day 120 prior to administration of ART.
Analyses included ultrasensitive HIV-1 RNA, anti-
retroviral drug concentration (plasma concentration
also measured), tryptophan/phenylalanine metabolites,
neopterin, and infectivity assays.
Cerebrospinal fluid HIV-1 RNA was measured
using a high sensitivity in-house assay with a detection
limit of 5 RNA copies/mL.22 Concentrations of ralte-
gravir and dolutegravir were analyzed by high-per-
formance-liquid-chromatography (HPLC) tandem mass
spectrometry.23 The lower limits of quantification
(LLQ) in plasma and cerebrospinal fluid were, respect-
ively, 5 and 1.95 ng/mL for raltegravir alongside 10
and 0.75 ng/mL for dolutegravir.
Plasma and cerebrospinal fluid concentrations of
tryptophan, kynurenine, phenylalanine, tyrosine and
neopterin were measured using previously described
methodologies.24 The kynurenine/tryptophan and
phenylalanine/tyrosine ratios were calculated as
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indexes of indoleamine 2,3-dioxygenase (IDO-1) and
phenylalanine hydroxylase (PAH) activity,
respectively.
Cerebrospinal fluid infectivity assays were under-
taken using cell cultures as previously described
in detail.25
Statistical analysis
All statistical analyses were performed using SPSS
(version 24.0; SPSS Inc., Chicago, IL, USA). As a
proof of concept study, no specific power calculations
were undertaken.
Cognitive results were analyzed in accordance with
CogStateTM recommendations. Z-standardized scores
for each participant in each cognitive task were esti-
mated using task-specific means and standard devia-
tions at baseline. Data are presented as global
cognitive scores, calculated as a composite of all cog-
nitive tasks. Where necessary, change of sign was
undertaken in order for the scoring of all tasks to be
unidirectional (the higher the score, the better the
performance).
Means and standard deviation of cerebral metabolite
ratios were calculated. Absolute changes in cerebral
metabolite ratios between baseline and follow-up were
evaluated using a paired sample t-test.
Geometric means (GM) and 95% confidence inter-
vals (CIs) were calculated for cerebrospinal fluid and
plasma concentrations of raltegravir and dolutegravir.
The CIs were first determined using logarithms of the
individual GM values and then the calculated values
were expressed as linear values. A coefficient of vari-
ation (CV, [(standard deviation/mean) 100]) was
used to express inter-patient variability in the pharma-
cokinetic parameters.
Comparisons between the study arms for cerebral
function parameters were undertaken using appropriate
statistical methods which included paired and inde-
pendent t-tests, chi-squared or Fisher’s exact tests and
Mann–Whitney U-test. Spearman’s rank correlation
was used to investigate associations between changes
in PROMs and cerebral metabolite ratios
For the tryptophan pathway metabolites, paired-
samples t-tests were undertaken to assess changes in
plasma and cerebrospinal fluid concentrations over the
study period for each arm independently. Pearson r
correlations were used to determine associations
between cerebral parameters and global cognitive
scores for all subjects at baseline. Mixed models were
constructed to investigate the relationship between
changes in metabolite concentrations in plasma and
cerebrospinal fluid with the global cognitive score for
subjects in the dolutegravir arm (switch arm) only. The
models fixed effects were global cognitive score
(dependent variable) with the biomarker concentrations
the independent variable. The alpha value was set at




Of 28 participants screened, 22 were randomized and
20 completed study procedures (8 in the control arm
and 12 in the switch arm, see Figure 1). Baseline char-
acteristics are shown in Table 1. Study drugs were
generally well-tolerated with all patients reporting over
95% adherence to therapy. No safety or laboratory
concerns related to study drugs were observed. One
patient in the switch arm died during the study follow-
up due to complications arising from a previously
undiagnosed metastatic malignancy. At day 120,
plasma HIV-1 RNA was <20 copies/mL in
all subjects.
Cognitive results and patient reported
outcome measures
Baseline cognitive performance and changes over the
study period as shown in Table 2. No statistically sig-
nificant differences between the study groups were
observed in changes in global cognitive score or in
individual cognitive domains (all p-values >0.1). No
differences in changes in depression questionnaires
between the study arms were observed at day 120
from baseline (p¼ 0.57 for PHQ-9 and p¼ 0.38 for
Beck’s, see Table 2). The result of the Lawton’s instru-
mental activities of daily living scale questionnaire
was 8 for all patients at all time-points.
Neuroimaging
Cerebral metabolite ratio results are shown in Table 3.
No statistically significant changes in cerebral metab-
olite ratio were observed over the study period
between the two study treatment groups and no signifi-
cant associations were observed between the PROMs
and changes in cerebral metabolite ratios (p> 0.2 for
all associations).
Cerebrospinal fluid and plasma parameters
In all individuals, cerebrospinal fluid HIV-1 RNA was
undetectable (<5 copies/mL) at both baseline and day
120. Cerebrospinal fluid GM concentrations of ralte-
gravir for the control arm at baseline (n¼ 8), control
arm at day 120 (n¼ 8) and switch arm at baseline
(n¼ 12) were 16.2 ng/mL (95% CI: 9.4–27.9), 15.0 ng/
mL (95% CI: 8.6–26.3) and 14.8 ng/mL (95% CI:
8.2–26.8), respectively. Cerebrospinal fluid GM
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concentrations of dolutegravir for the switch arm at
day 120 (n¼ 12) was 7.6 ng/mL (95% CI: 5.2–11.1).
See Table 4 for full pharmacokinetic results.
Concentrations of tryptophan, kynurenine, phenyl-
alanine, tyrosine, and neopterin, and the tryptophan/
kynurenine and phenylalanine/tyrosine ratios, are
Figure 1. Consort diagram of participant flow. ARV, antiretroviral; DTG, dolutegravir; FTC, emtricitabine; LP, lumbar punc-
ture; MRI, magnetic resonance imaging; RAL, raltegravir; TDF, tenofovir disoproxil fumarate.
Table 1. Participant demographics and clinical characteristics.
Parameter Overall
Study arms
Control arm Switch arm
Mean (SD) unless otherwise stated
N 21 8 13
Age, years (IQR) 43 (11.5) 39.5 (15.5) 43 (13)
Male, n (%) 20 (95.2) 7 (87.5) 13 (100)
Ethnicity (%)
White 14 (66.7) 5 (62.5) 9 (69.2)
Black 2 (9.5) 1 (12.5) 1 (7.7)
Other 5 (23.8) 2 (25) 3 (23)
BMI 26.1 (3.2) 27.4 (3.4) 25.4 (2.9)
Baseline absolute CD4þ count (cells/mL) 717 (298) 688 (395) 736 (237)
Baseline CD4þ percentage, median (IQR) 34 (14.5) 35.5 (24.2) 34 (13)
Day 120 parameters
Number completing all study procedures 20 8 12
HIV RNA <20 copies/mL, n (%) 20 (100) 8 (100) 12 (100)
Absolute CD4þ count (cells/uL) 768 (389) 807 (535) 742 (277)
BMI, body mass index; IQR, interquartile range; SD, standard deviation.
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shown in Table 5. In the switch arm, mean plasma
concentration of tryptophan increased significantly
from baseline to day 120 (mean increase, 4.84 mmol/L;
p¼ 0.038; 95% CI, 0.32–9.37). No other statistically
significant changes in concentrations of the other
measured plasma biomarkers were observed in either
Table 2. Changes in cognitive function and patient reported outcome measures by study arm at day 120.
Baseline Changes at day 120 from baseline
Control arm Switch arm Control arm Switch arm
Difference control
vs. switch arm




Cognitive testing, Z-scorea (SD)
Global cognitive score 0.25 (0.54) 0.15 (0.70) 0.14 (0.37) 0.14 (0.40) 0.004
(0.38/0.37)
0.98
Patient reported outcome measures, median (range)
Patient Health
Questionnaire-9
2 (0/6) 2 (0/9) 0 (5/1) 0.5 (5/3) – 0.57b
Beck’s depression
questionnaire
3 (1/12) 1 (0/20) 1.5 (10/2) 1.0 (15/9) – 0.38b
CI, confidence interval; SD, standard deviation.
aLower result represents worse performance; higher results represent better performance.
bIndependent samples Mann–Whitney U-test.







study groups over 120 days, mean (SD)
Correlation with change in
depression questionnaires





n¼8 n¼12 n¼7 n¼12 p-value PHQ-9a Beck’sa
Frontal gray matter
NAA/Cr 1.04 (0.11) 1.00 (0.09) 0.06 (0.16) 0.08 (0.14) 0.07 0.38 (0.10) 0.22 (0.36)
Cho/Cr 0.22 (0.02) 0.24 (0.03) 0.01 (0.02) 0.01 (0.04) 0.21 0.43 (0.06) 0.36 (0.13)
mI/Cr 0.57 (0.06) 0.58 (0.11) 0.04 (0.03) 0.07 (0.41) 0.85 0.13 (0.60) 0.27 (0.25)
Frontal white matter
NAA/Cr 1.28 (0.41) 1.16 (0.15) 0.13 (0.34) 0.01 (0.13) 0.20 0.18 (0.44) 0.08 (0.73)
Cho/Cr 0.32 (0.04) 0.31 (0.04) 0.004 (0.05) 0.01 (0.05) 0.75 0.26 (0.28) 0.07 (0.78)
mI/Cr 0.71 (0.19) 0.63 (0.12) 0.02 (0.05) 0.005 (0.11) 0.82 0.09 (0.72) 0.01 (0.95)
Right basal ganglia
NAA/Cr 0.97 (0.18) 0.92 (0.20) 0.13 (0.24) 0.0066 (0.33) 0.35 0.06 (0.80) 0.006 (0.98)
Cho/Cr 0.25 (0.02) 0.23 (0.02) 0.03 (0.03) 0.004 (0.05) 0.21 0.03 (0.89) 0.14 (0.56)
mI/Cr 0.48 (0.10) 0.38 (0.10) 0.04 (0.10) 0.07 (0.19) 0.16 0.10 (0.65) 0.23 (0.33)
Cho, choline; Cr, creatinine; mI, myoinositol; NAA, N-acetyl aspartate; PHQ-9, Patient Health Questionnaire-9; SD, standard deviation.
aCorrelation between change in cerebral metabolite ratios over 120 days and change in questionnaires over 120 days.









GM (95%CI) CV% GM (95%CI) CV% GM (95%CI) CV%
Raltegravir at baseline
Plasma 116 (66–204) 93.8 102 (34–310) 109.9 126 (59–266) 87.6
CSFa 15.4 (10.5–22.4) 66.3 16.2 (9.4–27.9) 60.6 14.8 (8.2–26.8) 72.0
CSF:plasma % 13.0 (8.6–19.4) 122.9 15.8 (6.4–39.3) 125.7 11.2 (7.4–17.0) 51.7
Raltegravir at follow-up
Plasma – – 107 (39–293) 113.6 – –
CSF – – 15.0 (8.6–26.3) 73.5 – –
CSF:plasma % – – 14.0 (7.3–26.9) 74.7 – –
Dolutegravir at follow-up
Plasma – – – – 1052 (742–1492) 58.3
CSF – – – – 7.6 (5.2–11.1) 54.7
CSF:plasma % – – – – 0.7 (0.6–0.8) 28.4
CSF, cerebrospinal fluid; CV, coefficient of variation; GM, geometric mean.
aOne patient with [raltegravir]CSF < LLQ (1.950 ng/mL) in switch group.
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arm. Statistically significant differences in plasma tryp-
tophan (p¼ 0.011) and cerebrospinal fluid neopterin
concentrations (p¼ 0.049) were observed between
arms at day 120.
All cerebrospinal fluid samples displayed dose–res-
ponse curves allowing quantification of antiretroviral
activity on infectivity assays. At a 1:4 dilution, all
cerebrospinal fluid samples from both study arms pre-
sented near-maximal inhibition at both time points.
Infectivity model half maximal inhibitory IMIC50
expressed as CNS Anti-Retroviral scores
(Log2IMIC50) of cerebrospinal fluid samples did not
show statistically significant changes between baseline
and day 120 for both study groups (p¼ 0.36 for con-
trol group and p¼ 0.27 for switch group).
Associations with tryptophan metabolites
No statistically significant associations were observed
between plasma kynurenine or tyrosine pathway
metabolites and global cognitive scores at baseline (all
p values >0.1). Cerebrospinal fluid phenylalanine con-
centrations positively correlated with baseline global
cognitive scores (r¼ 0.49, unadjusted p¼ 0.024), as
did cerebrospinal fluid phenylalanine/tyrosine ratios
(r¼ 0.57, unadjusted p¼ 0.007).
In the mixed model analysis of the switch arm
(dolutegravir), plasma kynurenine/tryptophan ratio
concentrations correlated with changes in global cogni-
tive scores, such that for every 1 mmol/L increase
observed in kynurenine/tryptophan ratio, a 0.019-point
decrease was observed in the global cognitive scores
(unadjusted p¼ 0.021), indicating poorer cognitive per-
formance as the kynurenine/tryptophan ratio increases.
No other statistically significant associations were
observed for the other biomarkers tested in either
plasma or cerebrospinal fluid.
Discussion
In this randomized, prospective, proof of concept
study, comparing switching integrase inhibitor-based
ART in PWH without overt neuropsychiatric symp-
toms, we observed no differences in cognitive function
or other cerebral function parameters over a 120-day
period. Strengths of our study include the randomized
approach to the study design and the detailed cerebral
function assessments which were included, namely
cognitive function, PROMs, neuroimaging parameters
and several cerebrospinal fluid parameters.
In large cohort studies, neuropsychiatric adverse
events have been frequently observed in PWH on inte-
grase inhibitors, with the presence of these neuro-
psychiatric adverse events associated with an increased
risk of discontinuing ART therapies.13 We specifically
recruited PWH without overt neurological symptom-
atology. During the follow up period no neuropsychi-
atric adverse events evolved in our study. It is likely
the population we have recruited were less prone to
develop such neuropsychiatric side effects given we
Table 5. Tryptophan metabolism parameters in plasma and CSF over study period.
Parameter













TRP; mmol/L, mean (SD) 51.15 (10.56) 50.15 (8.03) 4.06 (6.61) 4.84 (7.12) 0.011
KYN; mmol/L, mean (SD) 1.98 (0.78) 2.07 (0.69) 0.06 (0.40) 0.10 (0.64) 0.541
KYN/TRP ratio; mmol/mmol,
mean (SD)
38.82 (12.90) 41.15 (9.49) 3.24 (11.63) 0.55 (12.60) 0.506
PHE; mmol/L, mean (SD) 61.65 (7.55) 58.38 (9.05) 3.83 (11.36) 3.82 (8.90) 0.109
TYR; mmol/L, mean (SD) 65.34 (8.49) 65.44 (15.00) 1.38 (14.82) 3.78 (10.76) 0.378
PHE/TYR ratio; mmol/mmol,
mean (SD)
0.96 (0.15) 0.92 (0.18) 0.03 (0.17) 0.01 (0.14) 0.589
NEO; nmol/L, mean (SD) 11.83 (8.50) 12.30 (5.89) 3.61 (11.55) 5.23 (15.42) 0.803
Cerebrospinal fluid
TRP; mmol/L, mean (SD) 1.58 (0.68) 1.67 (0.26) 0.02 (0.33) 0.17 (0.43) 0.406
KYN; mmol/L, mean (SD) 0.07 (0.03) 0.06 (0.03) 0.01a (0.01) 0.01b (0.01) 0.130
KYN/TRP ratio; mmol/mmol,
mean (SD)
43.39 (29.17) 38.77 (15.78) 5.27a (10.95) 0.48b (10.79) 0.513
PHE; mmol/L, mean (SD) 12.31 (2.43) 11.73 (2.02) 0.33 (1.60) 0.22 (2.17) 0.553
TYR; mmol/L, mean (SD) 12.38 (3.28) 11.83 (2.61) 0.14 (2.81) 0.82 (1.94) 0.379
PHE/TYR ratio; mmol/mmol,
mean (SD)
1.01 (0.10) 1.01 (0.16) 0.00 (0.18) 0.04 (0.14) 0.565
NEO; nmol/L, mean (SD) 9.19 (8.20) 7.70 (4.26) 1.93 (2.54) 0.23 (2.03) 0.049
CI, confidence interval; DTG, dolutegravir; KYN, kynurenine; NEO, neopterin; PHE, phenylalanine; RAL, raltegravir; SD, standard devi-
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recruited individuals tolerating a raltegravir containing
ART regimen without adverse events and who were
willing to switch the integrase inhibitor component of
their ART regimen.26
In a retrospective cross-sectional study assessing
tryptophan metabolism in individuals with acute HIV
infection, increased kynurenine/tryptophan ratios are
described to be associated with increased depressive
symptoms.27 Furthermore, in PWH with cognitive
impairment higher phenylalanine/tyrosine ratios, repre-
senting an increased CNS PAH activity, were observed
when compared to PWH without cognitive disorders.27
In another retrospective cross-sectional study in viro-
logically suppressed PWH, higher phenylalanine/tyro-
sine ratios were observed, but these were not
associated with cognitive impairment.24 Also, a trend
towards lower plasma kynurenine/tryptophan ratios
was associated with both cognitive impairment and
depression.24 In a further prospective study assessing
PWH switching from efavirenz-based ART to dolute-
gravir-based ART, an increase in plasma kynurenine
concentrations and improvements in CNS toxicity
scores was reported.28 In our study, we did not observe
differences in either phenylalanine/tyrosine ratio in
plasma or cerebrospinal fluid between study arms.
However, plasma kynurenine/tryptophan ratios were
found to be negatively correlated with lower global
cognitive scores in the switch arm. These results
should be interpreted with caution since this model
was not adjusted for multiplicity and changes in the
kynurenine/tryptophan ratio or global cognitive score
were not observed separately in the individual study
arms. In addition, this significant relationship was not
present for the cerebrospinal fluid kynurenine/trypto-
phan ratio.
A difference in mean plasma tryptophan concentra-
tions was observed between the study groups
(p¼ 0.011) at day 120. This appears to be driven by an
increase in plasma tryptophan in the switch arm (mean
change 4.84 mmol/L; SD: 7.12) and a decrease in the
control arm (mean change 4.6 mmol/L; SD: 6.61).
Corresponding changes in kynurenine concentrations
or the kynurenine/tryptophan ratio were not observed
indicating that the observed changes are unlikely
related to changes in IDO-1 enzyme activity as both
changes in tryptophan and kynurenine concentrations
would be expected. Given these differences are
unlikely to be related to changes in IDO-1 enzyme
activity it is possible the differences are not related to
ART treatment effects in our study. Other possible
explanations for the changes in plasma tryptophan con-
centration we have observed may be related to dietary
intake which is known to affect plasma tryptophan
concentration.29,30 We did not undertake dietary
assessments in our study to assess any changes in diet-
ary intake. Another limitation of the study is the lack
of a negative HIV control group. This prevents from
examining the associations of cerebral function param-
eters and tryptophan/phenylalanine metabolites.
We observed a difference in mean cerebrospinal
fluid neopterin concentration between study arms at
follow up (p¼ 0.049). This change in cerebrospinal
fluid neopterin concentration was not associated with
any other clinical parameters and therefore any clinical
relevance of this observation is unclear. Neopterin was
included as a marker of immune activation based on
its correlation with IDO activity.31
In a proof of concept study like this, the use of indi-
cators of effect size could be very relevant to establish
a hypothesis where non-statistically significant results
are observed. This is the case for a trend of NAA/Cr
ratio changes in the frontal gray matter favoring the
switch arm (p¼ 0.07). However, this finding in isola-
tion is particularly difficult to interpret since that dif-
ference involves an unexplained and unexpected
worsening in NAA/Cr ratio in the control arm. See
Table 3.
Cerebrospinal fluid concentrations of dolutegravir
[7.6 ng/mL (95% CI, 5.2–11.1] were in a similar range
to those previously reported [13 ng/mL (range,
4–18 ng/mL)].32 Other studies have described associa-
tions between dolutegravir cerebrospinal fluid concen-
tration and neuropsychiatric adverse events.33 Given
our study comprised of PWH without overt neuro-
psychiatric adverse events, we do not have the ability
to link the cerebrospinal fluid exposure of dolutegravir
to such events. Other limitations of our study are the
small sample size, the relative young age of the partici-
pants and the small number of female participants.14
In summary, we observed no significant changes in
clinical, cerebral imaging parameters or cerebrospinal
fluid biomarkers in this comprehensive assessment of
cerebral pharmacodynamic and pharmacokinetic
parameters in virologically suppressed PWH without
overt neuropsychiatric switching integrase inhibitor.
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